- Case report
- Open Access
Presentation of two patients with malignant granulosa cell tumors, with a review of the literature
© Tamura et al.; licensee BioMed Central Ltd. 2012
Received: 7 June 2012
Accepted: 20 August 2012
Published: 11 September 2012
Granulosa cell tumors (GCTs) of the ovary account for 2 to 5 of ovarian malignancies. We present two patients with malignant ovarian adult GCT. In one patient, a combination of bleomycin, etoposide, and cisplatin was effective after initial surgery for malignant GCT. In the other, an aromatase inhibitor was effective for recurrent malignant GCT. We also review the literature for further management of this tumor. Because GCT of the ovary is rare, it will be necessary to elucidate the clinical phenotype and establish treatment protocols by accumulating and analyzing more patients.
Granulosa cell tumors (GCTs) of the ovary comprise 2 to 5% of malignant ovarian tumors [1, 2], and 20 to 30% show malignant clinical and histopathological characteristics. The clinical outcome for tumors at stages I and II is excellent, whereas those at stages III and IV remains poor . The 5-year survival rate for GCTs is approximately 80% overall, and some patients experience relapse 20 to 30 years after the initial surgery [4, 5]. There are few reports on the clinical phenotype of malignant progression , and no standard therapy has yet been established . We report our experience of two patients with malignant GCT, and review the literature.
A 26-year-old woman presented to her doctor in December 2010 with abdominal pain and bloating. She had never been pregnant, but had a history of surgery for patent ductus arteriosus (at the age of 1 year) and also had type 2 diabetes. A pelvic neoplasm was suspected, and the patient was referred our department in January 2011 for detailed investigation and treatment.
Abdominal ultrasonography showed a mass, with hyperechogenicity. On magnetic resonance imaging (MRI) scan, an irregular, solid mass, 130 mm in size, was seen in the peritoneal cavity with associated pelvic ascites. Computed tomography (CT) showed enlargement of the left subclavian, para-aortic, and pelvic lymph nodes, and metastasis was thus suspected. No abnormality was seen with peripheral blood tests and biochemical tests, but the level of a tumor marker, CA125, was raised (233 U/ml; normal range 0 to 35 U/ml).
A diagnosis of malignant ovarian tumor was made, and surgery was performed. The laparoscopic findings indicated that the mass was an irregular, solid tumor derived from the left ovary. Because multiple distant metastases were present, a left adnexectomy was performed.
Based on these results, a malignant GCT of the ovary (Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IV) was diagnosed. After surgery, the patient was given three cycles of chemotherapy (BEP: bleomycin 20 mg/m2 on days 2, 9, and 16; etoposide 100 mg/m2 on days 1 to 3; cisplatin 15 mg/m2 on days 1 to 5) every 3 weeks.
A CT scan performed after the completion of two cycles showed a reduction in the size of lesions in lymph nodes at all sites. However, pyrexia and respiratory discomfort occurred, and worsened after the completion of three cycles. The patient was treated for a provisional diagnosis of drug-induced interstitial pneumonia, but her respiratory condition failed to improve, and she died as a result of respiratory failure caused by interstitial pneumonia.
A 59-year-old woman was diagnosed with an ovarian tumor in December 1998, for which she underwent laparotomy. She had been pregnant four times and had three children; she had no other medical history of note.
Based on the above results, a malignant GCT was diagnosed. Oral administration of anastrozole 1 mg/day has continued with the patient followed up as an outpatient, and this has resulting in disease-free survival to the most recent follow-up (April 2012).
Ovarian GCT is classified as a sex cord-stromal tumor and is treated as a borderline malignant tumor. These tumors show the clinical and pathological features of malignancy at a rate of 20 to 30%, and comprise 2 to 5% of ovarian malignant tumors [1, 2]. Prognostically, the 5-year survival rate of patients with stage I or II disease is thought to be 95%, and that of patients with stage III or IV disease is 59% . However, some patients experience relapse 20 to 30 years after the initial surgery [4, 5], and there have been a few reports published on the clinical phenotype of those with rapid progression . Jozwicki et al. reported a patient with a very aggressive ovarian GCT, composed of granulosa, sarcomatoid, and fibrothecomatous tissues . The tumor recurred rapidly, and the patient died 16 months later .
The histopathological characteristics of GCTs include cells with a coffee bean-like longitudinal nuclear groove and a micro-follicular structure termed the ‘Call-Exner body’. In patients with malignancy, a large number of mitoses and dyskaryoses are also seen. According to one report, the number of mitoses is a pathological prognostic factor . Alpha Inhibin-alpha is a sensitive immunohistochemical marker of GCT of the ovary, and is of value in the differential diagnosis of ovarian neoplasia  as shown in the two patients presented.
Because it is difficult to distinguish GCTs from epithelial ovarian tumors pre-operatively, and because the accuracy of intraoperative rapid pathological diagnosis is not good, basic techniques used for the management of ovarian cancer (bilateral adnexectomy plus+total hysterectomy+plus omentectomy) and staging laparotomy are recommended as the initial therapy . Indications and protocols for adjuvant therapy have not yet been established because GCTs are rare, and a large-scale clinical study has not been conducted. In general, chemotherapy is recommended for patients with residual foci, a high risk of recurrence (tumor rupture, stage Ic or greater, a poorly differentiated tumor, or a tumor diameter of >100 to 150 mm); or actual recurrence. PVB (cisplatin + vinblastin + bleomycin) therapy  and BEP (bleomycin + etoposide + cisplatin) therapy  are considered effective regimens, based on the results of clinical studies that showed a relatively high response rate. The target of both therapies is the progressive, recurrent GCT, and the response rates to PVB and BEP therapies were given as 60.5% and 37%, respectively [12, 13]. Although retrospective, a study of the combination therapy of taxane-based drugs and platinum-based drugs in patients with recurrences showed a response rate of 54% . Drugs with an anti-estrogenic effect, such as gonadotropin-releasing hormone agonists and aromatase inhibitors, have recently been suggested to be effective [15–17]. Aromatase inhibitors exhibit an anti-estrogen effect by binding to aromatase, an enzy\me required for the conversion of androgen to estrogen, and inhibiting its activity. Although aromatase inhibitors are used clinically to treat post-menopausal women with estrogen receptor-positive breast cancer , there are some reports of patients in whom an aromatase inhibitor was effective against GCTs with repeated recurrences [15–17], as for patient 2.
Patient 1 had a reduction in the size of lesions in lymph nodes after BEP therapy, confirming the efficacy of the treatment. However, because serious interstitial pneumonia also occurred in this patient, as has been reported for other cases in which bleomycin was implicated in treatment-related death, the use of this treatment needs to be reconsidered. By contrast, even though the intraperitoneal tumor recurred in patient 2 after the start of aromatase inhibitor administration, the tumors were small, suggesting that the aromatase inhibitor slowed tumor growth, and that this drug is effective against recurrent tumors.
The results for our two patients suggest that BEP therapy is effective after initial surgery and that an aromatase inhibitor is effective for recurrent tumors. However, because GCTs are rare, it will be necessary to elucidate the clinical phenotype and establish treatment protocols by accumulating and analyzing more patients.
Written informed consent was obtained from the patient or the patient’s family for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
RT, TY, YM, KA and RT work as instructors at Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine. YY is an associate professor and HM is a professor and is also chair of the Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine.
- Fox HAK, Langley FA: A clinicopathologic study of 92 cases of granulosa cell - tumor of the ovary with special reference to the factors influencing prognosis. Cancer. 1975, 35: 231-241. 10.1002/1097-0142(197501)35:1<231::AID-CNCR2820350128>3.0.CO;2-O.View ArticlePubMedGoogle Scholar
- Pectasides D, Pectasides E, Psyrri A: Granulosa cell tumor of the ovary. Cancer Treat Rev. 2008, 34: 1-12.View ArticlePubMedGoogle Scholar
- Piura B, Nemet D, Yanai-Inbar I, Cohen Y, Glezerman M: Granulosa cell tumor of the ovary: a study of 18 cases. J Surg Oncol. 1994, 55: 71-77. 10.1002/jso.2930550203.View ArticlePubMedGoogle Scholar
- Chen YC, Chnag LC, Soong RS: A late recurring and easily forgotten tumor: ovarian granulosa cell tumor. World J Surg Oncol. 2012, 10: 85-10.1186/1477-7819-10-85.PubMed CentralView ArticlePubMedGoogle Scholar
- Hines JFKM, Moore JL, Fine KP, Lage JM, Barnes WA: Recurrent granulosa cell tumor of the ovary 37 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol. 1996, 60: 484-488. 10.1006/gyno.1996.0078.View ArticlePubMedGoogle Scholar
- Jozwicki W, Brozyna AA, Walentowicz M, Grabiec M: Bilateral aggressive malignant granulosa cell tumour with essentially different immunophenotypes in primary and metastatic lesions comprising predominatly sarcomatoid and fibrothecomatous pattern – looking for prognostic markers: a case report. Arch Med Sci. 2011, 5: 918-922.View ArticleGoogle Scholar
- Lee YK, Park NH, Kim JW: Characteristics of recurrence in adult type granulosa cell tumor. Int J Gynecol Cancer. 2008, 18: 642-647. 10.1111/j.1525-1438.2007.01065.x.View ArticlePubMedGoogle Scholar
- Zang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, Berek JS, Osann K, Chan JK: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary – an analysis of 376 women. Gynecol Oncol. 2007, 104: 396-400. 10.1016/j.ygyno.2006.08.032.View ArticleGoogle Scholar
- Malmström H, Högberg T, Risberg B, Simonsen E: Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol. 1994, 52: 50-55. 10.1006/gyno.1994.1010.View ArticlePubMedGoogle Scholar
- Ciriş M, Erhan Y, Zekioglu O, Bayramoglu H: Inhibin alpha and beta expression in ovarian stromal tumors and their histological equivalences. Acta Obstet Gynecol Scand. 2004, 83: 491-496.PubMedGoogle Scholar
- Ovarian Cancer Guideline (Version 1. 2009). NCCN Clinical Practice Guidelines in Oncology.http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf,
- Pecorelli S, Wagenaar HC, Vergote IB, Curran D, Beex LV, Wiltshaw E, Vermorken JB: Cisplatin (P), vinblastine (V) and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(−theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer. 1999, 35: 1331-1337. 10.1016/S0959-8049(99)00142-2.View ArticlePubMedGoogle Scholar
- Homesley HD, Bundy BN, Hurteau JA, Roth LM: Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 1999, 72: 131-137. 10.1006/gyno.1998.5304.View ArticlePubMedGoogle Scholar
- Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, Gershenson DM: The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005, 97: 489-496. 10.1016/j.ygyno.2005.01.011.View ArticlePubMedGoogle Scholar
- Freeman SA, Modesitt SC: Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol. 2006, 103: 755-758. 10.1016/j.ygyno.2006.06.022.View ArticlePubMedGoogle Scholar
- Korach J, Perri T, Beiner M, Davidzon T, Fridman E, Ben-Baruch G: Promising effect of aromatase inhibitors on recurrent granulosa cell tumors. Int J Gynecol Cancer. 2009, 19: 830-833. 10.1111/IGC.0b013e3181a261d7.View ArticlePubMedGoogle Scholar
- Alhilli MM, Long HJ, Podratz KC, Bakkum-Gamez JN: Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature. J Obstet Gyaecol Res. 2012, 38: 340-344. 10.1111/j.1447-0756.2011.01698.x.View ArticleGoogle Scholar
- Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008, 9: 45-53.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.